Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FRISCO, Texas and MT LAUREL, N.J., Dec. 08, 2016 -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, today announced that its Greatbatch Medical subsidiary has signed a development agreement with Impulse Dynamics to co-develop its next generation Lead System for Cardiac Contractility Modulation (CCM) therapy. In addition, the companies also have agreed to negotiate a supply agreement for the associated products under the development agreement.
|
|||
CCM is a unique and innovative method for treating moderate-to-severe heart failure by delivering non-excitatory electrical pulses to the heart. By leveraging Integer’s existing technology platform with Impulse Dynamics’ unique specifications, Impulse Dynamics will be able to deliver a fully customized lead solution to the CCM market 12 to 16 months earlier than developing one on their own. Clinical trials have shown that CCM treatment significantly improves exercise tolerance and quality of life in a subset of symptomatic heart failure patients. According to the Journal of the American College of Cardiology, heart failure is a global public health problem affecting an estimated 26 million worldwide. In the United States alone, the prevalence is 5.7 million with 670,000 new cases each year. More information about CCM therapy can be found here.
“We look forward to growing our cooperation with the Integer organization. We believe that Integer’s proven track record in implantable device development will accelerate the successful delivery of Impulse Dynamics’ next-generation cardiac stimulation lead specifically designed for the most effective delivery of CCM therapy to heart failure patients," said David Prutchi, executive vice-president, product development at Impulse Dynamics.
“This is an exciting collaboration for Integer and a successful expansion of our long-standing relationship with Impulse Dynamics,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management & Neuromodulation product line. “This agreement further enhances Integer’s position as a key developer and manufacturer of Leads for our customers in the active implantable market and also speaks to our full systems capabilities to deliver innovative solutions efficiently that meet our customer’s needs quickly.”
About Integer™
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.integer.net.
About Impulse Dynamics
Impulse Dynamics N.V., a member of the Hobart Group companies, is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the United States, Europe, Asia, and Australia. For more information please visit www.impulse-dynamics.com. CCM and Optimizer are trademarks of Impulse Dynamics N.V.
About the Hobart Group
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have nearly 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the United States and Asia. For more information, visit www.hobart-group.com.
Impulse Dynamics Contact Media Relations Sharon Alon [email protected] 972 54 430 37 87 Integer Contacts Investor Relations Amy Wakeham [email protected] 214.618.4978 Media Relations Jeannine Lee [email protected] 972.668.4593
